Azetidinones as vasopressin V1a antagonists

Abstract

The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC 50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor. Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K i values < 1 nM and brain levels after oral dosing ~100-fold higher than receptor affinities.The neurohypophysial hormones vasopressin 1 and oxytocin exert a wide range of physiological effects through binding to specific membrane receptors belonging to the G protein-coupled receptor (GPCR) superfamily. To date, three vasopressin receptor subtypes and one oxytocin receptor have been pharmacologically and functionally described 1 . V1a, V1b, and oxytocin receptors activate phospholipase C, resulting in the production of inositol 1,4,5-trisphosphate and diacylglycerol, mobilization of intracellular calcium, and activation of protein kinase C. V2 receptors stimulate adenylyl cyclase, resulting in the accumulation of cyclic AMP and activation of protein kinase A. All four receptor subtypes from several mammalian species have been recently cloned 2-5 , as well as closely related receptors from bony fishes and invertebrates 6, 7 . Although vasopressin is perhaps best-known for its role in the cardiovascular system, it also has actions in the central nervous system (CNS), and several CNS applications of vasopressin receptor antagonists have been suggested (reviewed in references 8 and 9 ). A number of research groups have prepared antagonists directed at the vasopressin V1 receptor 10-15 . While V1a antagonists have been made, none of these have been reported to penetrate the CNS efficiently. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author ManuscriptBioorg Med Chem. Author manuscript; available in PMC 2007 November 8. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptOur vasopressin antagonist program was initiated to identify a CNS-active V1a antagonist: one with potent affinity for the human V1a receptor (IC 50 < 10 nM), good oral availability, and ability to penetrate the blood brain barrier -in short, a candidate for human clinical development targeting CNS disorders. The program began at Lilly in 1990 with the selection of a 1,500-compound "Neuropeptide Cassette" -a library intended to identify nonpeptide ligands for neuropeptide receptors. The library applied the concept of receptor crosstalk -previously well...

2-Azetidinone – A new profile of various pharmacological activities

“…For the identification of CNS-active V1a antagonist: one with potent affinity for the human V1a receptor (IC 50 < 10 nM), good oral availability, and ability to penetrate the blood brain barrierdin short, a candidate for human clinical development targeting CNS disorders, a novel series of vasopressin V1a antagonists has been designed from the unique monocyclic azetidinone platform by Guillon et al [100]. Subnanomolar affinities at the human V1a receptor have been achieved.…”

Synthesis and characterization of novel imidazoquinoline based 2-azetidinones as potent antimicrobial and anticancer agents

“…Modification of the b-lactam ring leads to compounds with diverse pharmacological activities, inducing cholesterol absorption inhibition, human tryptase, thrombin and chymase inhibition, vasopressin V1a antagonist activity, and antimicrobial, anticonvulsant and anti-inflammatory activities [4][5][6][7][8]. The drugs with 2-azetidinone scaffold are penicillins, cephalosporins, carbapenems, nocardicins, monobactams, clavulanic acid, sulbactams and tazobactams.…”

Synthesis and biological evaluation of some new β-lactam-triazole hybrids

“…In addition, it possess many other pharmacological activities such as human cytomegalovirus protease inhibitors (Borthwick et al, 1998), LHRH antagonists (Guillon et al, 2007), cholesterol absorption inhibitors (Burnett, 2004), anticancer agents (Banik et al, 2010;O'Boyle et al, 2010), antihyperglycemic (Goel et al, 2004, antimalarial (Jarrahpour et al, 2012), anti-HIV (Sperka et al, 2005), anti-inflammatory and analgesic activities (Saturnino et al, 2000).…”